Comparison of clinical outcomes of transjugular intrahepatic portosystemic shunt for refractory ascites and recurrent nonrefractory ascites

Table 4 Hepatic encephalopathy occurrence in the four groups of patients

Time	Group	HE occurrence		Occurrence rate (%)	χ2	P value
		Yes	No
1 month	A	25	158	13.66	6.462	0.004
	B	81	136	37.32
	C	69	259	21.03	5.357	0.07
	D	56	79	41.48
3 months	A	38	145	20.76	5.153	0.001
	B	101	116	46.54
	C	76	252	23.17	6.468	0.003
	D	65	70	48.14
6 months	A	30	142	17.44	6.269	0.006
	B	45	64	41.28
	C	57	244	18.93	7.356	0.005
	D	30	37	44.77
1 year	A	19	140	11.94	5.045	0.005
	B	9	19	32.14
	C	43	229	15.80	6.248	0.007
	D	4	9	44.44
2 years	A	12	119	9.16	5.327	0.006
	B	4	10	28.57
	C	25	204	10.91	4.253	0.003
	D	2	4	33.33
3 years	A	7	106	6.19	6.403	0.008
	B	2	4	33.33
	C	13	178	6.80	7.375	0.004
	D	1	2	33.33

HE: Hepatic encephalopathy. There were significant differences in the incidence of hepatic encephalopathy in group A compared with group B, group C compared with group D, at 1, 3, 6, 9 months, 1, 2 and 3 years (P < 0.05).